Phase 1 Non-Hodgkin Lymphoma Clinical Trials
117 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 117 trials
Recruiting
Phase 1Phase 2
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines645 enrolled127 locationsNCT05006716
Recruiting
Phase 1Phase 2
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Diffuse Large B Cell LymphomaNon-Hodgkin LymphomaLymphoma+1 more
National Cancer Institute (NCI)155 enrolled1 locationNCT03223610
Recruiting
Phase 1
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
High-grade B-cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)30 enrolled8 locationsNCT06015880
Recruiting
Phase 1Phase 2
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
Recurrent Mycosis FungoidesRefractory Mycosis FungoidesSezary Syndrome+5 more
City of Hope Medical Center78 enrolled4 locationsNCT03011814
Recruiting
Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Hoffmann-La Roche121 enrolled26 locationsNCT05169515
Recruiting
Phase 1Phase 2
A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
TORL Biotherapeutics, LLC155 enrolled3 locationsNCT07439653
Recruiting
Phase 1
A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
MSD R&D (China) Co., Ltd.100 enrolled15 locationsNCT06189391
Recruiting
Phase 1
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
Non-Hodgkin LymphomaHodgkin's Lymphoma
Baylor College of Medicine60 enrolled2 locationsNCT02917083
Recruiting
Phase 1
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Myelodysplastic SyndromeB-cell Non Hodgkin LymphomaRefractory Acute Myeloid Leukemia+16 more
Mayo Clinic99 enrolled2 locationsNCT03017820
Recruiting
Phase 1
Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
Recurrent B-Cell Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaRecurrent B Acute Lymphoblastic Leukemia+1 more
University of Michigan Rogel Cancer Center12 enrolled1 locationNCT07532525
Recruiting
Phase 1
CD45BE-HSPC + CART-45 Cells
Hodgkin LymphomaRichter's TransformationT-cell Non-Hodgkin Lymphoma+1 more
University of Pennsylvania42 enrolled1 locationNCT07451054
Recruiting
Phase 1
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
B-cell Non Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaRelapsed B-Cell Non Hodgkin Lymphoma
ADC Therapeutics S.A.200 enrolled42 locationsNCT04970901
Recruiting
Phase 1
CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
Recurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic Leukemia+5 more
Mayo Clinic25 enrolled1 locationNCT04892277
Recruiting
Phase 1
Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas
Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedMature T-Cell and NK-Cell Non-Hodgkin LymphomaFollicular Helper T-Cell Lymphoma+3 more
City of Hope Medical Center20 enrolled1 locationNCT07278856
Recruiting
Phase 1Phase 2
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Diffuse Large B-Cell Lymphoma+11 more
Yazeed Sawalha38 enrolled2 locationsNCT06536049
Recruiting
Phase 1Phase 2
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
Mature B-cell Non-Hodgkin Lymphoma
Hoffmann-La Roche65 enrolled30 locationsNCT05533775
Recruiting
Phase 1
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Non-Hodgkin LymphomaPlasmablastic LymphomaBurkitt Lymphoma+2 more
National Cancer Institute (NCI)25 enrolled1 locationNCT05389423
Recruiting
Phase 1
A Phase I Study of JLM019 Injection
Hodgkin LymphomaNon-Hodgkin LymphomaAdvanced Solid Tumor (Phase 1)
Jecho Biopharmaceuticals Co., Ltd.115 enrolled1 locationNCT07623850
Recruiting
Phase 1
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
Recurrent Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic LeukemiaRecurrent Non-Hodgkin Lymphoma+15 more
Sumithira Vasu54 enrolled2 locationsNCT05418088
Recruiting
Phase 1Phase 2
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaLarge B-cell Lymphoma+1 more
Lyell Immunopharma, Inc.270 enrolled34 locationsNCT05826535